secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2026-06-02T20:39:40+00:00
Accession:  0001628280-26-039818
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas to out-license ARV-806 after completing Phase 1 dose escalation
-----------------------------------------------------------------------

- Completed dose escalation enrollment for ARV-806 Phase 1 trial in KRAS G12D solid tumors.
- Will complete monotherapy dose escalation and share clinical data in 2026.
- Plans to seek out-licensing agreement for any additional ARV-806 trials.
- Cash, equivalents and marketable securities as of March 31, 2026 fund operations into H2 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000162828026039818/0001628280-26-039818-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000162828026039818/arvn-20260602.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-039818

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer